Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 3Gynecologic 2Genitourinary 2Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 5Colorectal Neoplasms 4Stomach Neoplasms 3Neoplastic Cells, Circulating 3Colonic Neoplasms 3Rectal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Salivary Gland Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mycosis Fungoides 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Docetaxel 4Cetuximab 4pembrolizumab 3Trastuzumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Biopsy 3trastuzumab deruxtecan 2sargramostim 2Taxes 2SS1(dsFv)PE38 2Radiotherapy 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Carboplatin 2Capecitabine 2zanidatamab 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1tanespimycin 1spartalizumab 1pertuzumab 1oncogene protein E7, Human papillomavirus type 16 1neratinib 1mercaptoundecahydrododecaborate 1larotrectinib 1fluoromisonidazole 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Flow Cytometry × Gastrointestinal × Clear all
NCT00904514 2018-10-05

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

National Institutes of Health Clinical Center (CC)

Terminated
241 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

Congenital Abnormalities, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Brenner Tumor, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sezary Syndrome, Stomach Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡